Assessment of Tachykinin Receptor 3′ Gene Polymorphism rs3733631 in Rosacea

Karpouzis, Anthony; Avgeridis, Paschalis; Tripsianis, Gregory; Gatzidou, Elisavet; Kourmouli, Niki; Veletza, Stavroula

doi:10.1155/2015/469402

Cited by 17 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…NOD2/CARD15 is a member of the N-terminal caspase recruitment protein domain family and participates in the inflammatory response mediated by toll like receptor (TLR) [ 21 ]. In turn, a genetic predisposition to carrying the rs3733631 polymorphic variant in the tachykinin receptor gene TACR3 was also observed in patients with rosacea [ 22 ]; notably, this is near the TLR2 gene locus at 4q25 [ 22 ]. It is therefore reasonable to suppose that the polymorphism in TACR3 might be involved in the development of rosacea by enhancing the expression of TLR2.…”

Section: Predisposing Factors For Rosaceamentioning

confidence: 99%

“…CGRP is involved in vasodilatation and substance P is important in the manifestation of edema in patients with rosacea via the neurokinin 1 receptors of the postcapillary venules [ 128 , 129 ]. Additional biologic actions of substance P in rosacea include mast cell degranulation, endothelial cell proliferation, and local axon reflex-associated vasodilatation [ 22 ].…”

Section: Neurovascular Dysregulationmentioning

confidence: 99%

See 1 more Smart Citation

Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition

Woo

Lim

Cho

et al. 2016

IJMS

137

155

View full text Add to dashboard Cite

Rosacea is a chronic cutaneous inflammatory disease that affects the facial skin. Clinically, rosacea can be categorized into papulopustular, erythematotelangiectatic, ocular, and phymatous rosacea. However, the phenotypic presentations of rosacea are more heterogeneous. Although the pathophysiology of rosacea remains to be elucidated, immunologic alterations and neurovascular dysregulation are thought to have important roles in initiating and strengthening the clinical manifestations of rosacea. In this article, we present the possible molecular mechanisms of rosacea based on recent laboratory and clinical studies. We describe the genetic predisposition for rosacea along with its associated diseases, triggering factors, and suggested management options in detail based on the underlying molecular biology. Understanding the molecular pathomechanisms of rosacea will likely aid toward better comprehending its complex pathogenesis.

show abstract

Section: Predisposing Factors For Rosaceamentioning

confidence: 99%

Section: Neurovascular Dysregulationmentioning

confidence: 99%

Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition

Woo

Lim

Cho

et al. 2016

IJMS

137

155

View full text Add to dashboard Cite

show abstract

“…The precise pathogenesis of rosacea is complex and remains unclear, although it is currently thought to have a genetic background, with neurovascular dysfunction, disorganized innate and acquired immunity (12). Karpouzis et al (13) observed a statistically significant predominance of tachykinin receptor 3 rs3733631 G allele in PPR, indicating it may predispose the evolution of the disease. Chang et al (14) suggested a role for antigen presentation by class II HLA in the etiology of rosacea by genome-wide association study (GWAS).…”

Section: Discussionmentioning

confidence: 99%

Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels

Wang

Wen

et al. 2020

Exp Ther Med

View full text Add to dashboard Cite

Papulopustular rosacea (PPR) is characterized by central facial erythema and transient papules and/or pustules, with or without telangiectases. The treatment of PPR is challenging due to the unclear and complex pathogenesis. In the present retrospective study, patients with PPR treated with oral minocycline and supramolecular salicylic acid (SSA) 30% chemical peels enrolled between June 2018 and June 2019 were evaluated. All patients were treated with 50 mg minocycline twice a day and SSA 30% twice a month. A total of 19 patients were enrolled and all received the therapy for 12 weeks. A significant reduction of rosacea severity was observed by Investigator Severity Assessment (ISA) after treatment; the mean score reduced from 3.32±0.6 at baseline to 0.89±0.7 (P<0.01) at 12 weeks. After 12 weeks, all patients achieved at least a 'moderate response' and 17 patients (89.47%) obtained 'excellent improvement' in the Investigator Global Assessment of efficacy. No obvious adverse reactions were observed during each patient's visit. In conclusion, the combination treatment of minocycline and SSA 30% was an effective therapy for PPR. The limitation of the present study was that it was a retrospective analysis; more high-quality, prospective, blinded, controlled clinical trials are required to evaluate the efficacy based on the current study.

show abstract

“…These studies show the microbes-gut-brain axis, which requires further exploration. Neurokinin B, which often accompanies the onset of rosacea, is also involved in the pathogenesis of PD [ 24 ]. For ages, doctors have been using tetracycline in the treatment of rosacea.…”

Section: Reviewmentioning

confidence: 99%

Parkinson’s Disease and Its Dermatological Associations: Is Your Skin Whispering You a Diagnosis?

Shah

Sagar

Alhumaidi

et al. 2020

Cureus

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disease characterized clinically by the triad of resting tremor, rigidity, and bradykinesia. Although PD is primarily known for motor disturbance, 98.6% of patients experience one or more non-motor symptoms at all stages of the disease. Dermatological disorders are discussed as common non-motor associations of PD since the 20th century. Many studies have shown that patients of PD are predisposed to skin disorders. This article is a traditional review done to analyze the association between PD and its dermatological manifestations. We did a literature search using six keywords in the PubMed database and took the relevant articles published in the last 10 years. We reviewed more than 100 articles, which also included animal studies. On meticulous review, we observed an increased incidence of certain skin disorders like seborrheic dermatitis, bullous pemphigoid, rosacea, and melanoma in patients of PD. These disorders share either common risk factors or underlying mechanisms revolving around genetics, immunology, inflammation, and pathophysiology of PD, but the exact causation yet seems obscured. We believe that this opens a horizon for more research in the link between the skin and nervous system. We also emphasize that the dermatologists, neurologists and general physicians should address the cutaneous disorders in PD timely, educate their patients, help them lessen the psychosocial distress, and improve their quality of life.

show abstract

Assessment of Tachykinin Receptor 3′ Gene Polymorphism rs3733631 in Rosacea

Cited by 17 publications

References 37 publications

Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition

Rosacea: Molecular Mechanisms and Management of a Chronic Cutaneous Inflammatory Condition

Retrospective analysis of 19 papulopustular rosacea cases treated with oral minocycline and supramolecular salicylic acid 30% chemical peels

Parkinson’s Disease and Its Dermatological Associations: Is Your Skin Whispering You a Diagnosis?

Contact Info

Product

Resources

About